Adjuvant Chemotherapy for Senior Patients After Resection of Colon Cancer

Chapter

Abstract

Colorectal cancer is a leading cancer in most developed countries. It predominantly affects older people, and its incidence increases with increasing age. Older people with cancer pose special challenges to the cancer physician. Older patients are often perceived to benefit less from cancer treatment because of limited life expectancy and competing causes of mortality. They are also perceived to experience greater toxicity because of diminished organ reserves and multiple comorbidities. Physicians themselves often perceive that older people are reluctant to undergo toxic chemotherapy. Older people may face greater socioeconomic barriers to receiving chemotherapy. This review will explore the pattern of use, preferences, benefits, and toxicity regarding the use of adjuvant chemotherapy in the elderly patient with stage III colon cancer. Additionally, this review will also examine the potential implications of treatment dose reduction, premature treatment stoppage, role of adjuvant chemotherapy for stage II disease, and the strategy of choosing the right patient and regimen.

Keywords

Colorectal Cancer Colon Cancer Adjuvant Chemotherapy Advanced Colorectal Cancer Comprehensive Geriatric Assessment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Abrams TA, Brightly R, Mao J et al (2011) Patterns of adjuvant chemotherapy use in a population-based cohort of patients with resected stage II or III colon cancer. J Clin Oncol 29:3255–3262PubMedCrossRefGoogle Scholar
  2. Allegra CJ, Yothers G, O’Connell MJ et al (2011) Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 29:11–16PubMedCrossRefGoogle Scholar
  3. Ananda S, Field KM, Kosmider S et al (2008) Patient age and comorbidity are major determinants of adjuvant chemotherapy use for stage III colon cancer in routine clinical practice. J Clin Oncol 26:4516–4517; author reply 4517–4518PubMedCrossRefGoogle Scholar
  4. Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–2351PubMedCrossRefGoogle Scholar
  5. Andre T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109–3116PubMedCrossRefGoogle Scholar
  6. Aparicio T, Desrame J, Lecomte T et al (2003) Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. Br J Cancer 89:1439–1444PubMedCrossRefGoogle Scholar
  7. Arias E (2010) United States life tables, 2006. National Vital Statistics Reports, Vol 58, No 21Google Scholar
  8. Arriagada R, Le Chevalier T, Pignon JP et al (1993) Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 329:1848–1852PubMedCrossRefGoogle Scholar
  9. Balducci L, Extermann M (2000) Management of cancer in the older person: a practical approach. Oncologist 5:224–237PubMedCrossRefGoogle Scholar
  10. Blanke CD, Bot BM, Thomas DM et al (2011) Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials. J Clin Oncol 29:2781–2786PubMedCrossRefGoogle Scholar
  11. Bonadonna G, Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10–15PubMedCrossRefGoogle Scholar
  12. Carroll L (1872) Through the looking-glass. Hayes Barton Press, Raleigh, p 72. ISBN ISBN 1593772165Google Scholar
  13. Cassidy J, Twelves C, Van Cutsem E et al (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13:566–575PubMedCrossRefGoogle Scholar
  14. Castiglione M, Gelber RD, Goldhirsch A (1990) Adjuvant systemic therapy for breast cancer in the elderly: competing causes of mortality. International Breast Cancer Study Group. J Clin Oncol 8:519–526PubMedGoogle Scholar
  15. Chang HJ, Lee KW, Kim JH et al (2011) Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer. Ann Oncol. doi: 10.1093/annonc/mdr329
  16. Choo PW, Lee KS, Owen RE et al (1990) Singapore – an ageing society. Singapore Med J 31:486–488PubMedGoogle Scholar
  17. Choo PW, Sahadevan S, Chee YC et al (1991) Health care services for the elderly – a Singapore perspective. Singapore Med J 32:319–323PubMedGoogle Scholar
  18. Comella P, Natale D, Farris A et al (2005) Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. Cancer 104:282–289PubMedCrossRefGoogle Scholar
  19. D’Andre S, Sargent DJ, Cha SS et al (2005) 5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: a north central cancer treatment group study. Clin Colorectal Cancer 4:325–331PubMedCrossRefGoogle Scholar
  20. de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947PubMedGoogle Scholar
  21. Dobie SA, Baldwin LM, Dominitz JA et al (2006) Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst 98:610–619PubMedCrossRefGoogle Scholar
  22. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators (1999) J Clin Oncol 17: 1356–1363Google Scholar
  23. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators (1995) Lancet 345:939–944Google Scholar
  24. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer (1998) J Clin Oncol 16: 301–308Google Scholar
  25. Extermann M (2006) Comorbidity and cancer. American Society of Clinical Oncology (ASCO) Educational bookGoogle Scholar
  26. Extermann M, Hurria A (2007) Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 25:1824–1831PubMedCrossRefGoogle Scholar
  27. Fata F, Mirza A, Craig G et al (2002) Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: a 10-year experience of the Geisinger Medical Center. Cancer 94:1931–1938PubMedCrossRefGoogle Scholar
  28. Feliu J, Escudero P, Llosa F et al (2005) Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. J Clin Oncol 23:3104–3111PubMedCrossRefGoogle Scholar
  29. Feliu J, Salud A, Escudero P et al (2006) XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 94:969–975PubMedCrossRefGoogle Scholar
  30. Ferrucci L, Guralnik JM, Cavazzini C et al (2003) The frailty syndrome: a critical issue in geriatric oncology. Crit Rev Oncol Hematol 46:127–137PubMedCrossRefGoogle Scholar
  31. Findlay MP, Griffin AM, Raghavan D et al (1991) Retrospective review of chemotherapy for small cell lung cancer in the elderly: does the end justify the means? Eur J Cancer 27:1597–1601PubMedCrossRefGoogle Scholar
  32. Folprecht G, Cunningham D, Ross P et al (2004) Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 15:1330–1338PubMedCrossRefGoogle Scholar
  33. Fried TR, Bradley EH, Towle VR et al (2002) Understanding the treatment preferences of seriously ill patients. N Engl J Med 346:1061–1066PubMedCrossRefGoogle Scholar
  34. Gill S, Loprinzi CL, Sargent DJ et al (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22:1797–1806PubMedCrossRefGoogle Scholar
  35. Goldberg RM, Tabah-Fisch I, Bleiberg H et al (2006) Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24:4085–4091PubMedCrossRefGoogle Scholar
  36. Gray R, Barnwell J, McConkey C et al (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370:2020–2029PubMedCrossRefGoogle Scholar
  37. Grem JL, Jordan E, Robson ME et al (1993) Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma. J Clin Oncol 11:1737–1745PubMedGoogle Scholar
  38. Gross CP, McAvay GJ, Krumholz HM et al (2006) The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening. Ann Intern Med 145:646–653PubMedGoogle Scholar
  39. NCCN Clinical Practice Guidelines in Oncology [NCCN Guidelines] (2011) Colon cancer version 1.2012. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 2 Nov 2011
  40. Haller DG, Catalano PJ, Macdonald JS et al (2005) Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 23:8671–8678PubMedCrossRefGoogle Scholar
  41. Haller DG, Cassidy J, Tabernero J et al (2010) Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): no impact of age on disease-free survival (DFS). J Clin Oncol 28(15s): abstract 3521Google Scholar
  42. Hamel MB, Teno JM, Goldman L et al (1999) Patient age and decisions to withhold life-sustaining treatments from seriously ill, hospitalized adults. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment. Ann Intern Med 130:116–125PubMedGoogle Scholar
  43. Hurria A, Togawa K, Mohile SG et al (2010) Predicting chemotherapy toxicity in older adults with cancer: a prospective 500 patient multicenter study. J Clin Oncol 28(15s): abstract 9001Google Scholar
  44. Hutchins LF, Unger JM, Crowley JJ et al (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341:2061–2067PubMedCrossRefGoogle Scholar
  45. Iwashyna TJ, Lamont EB (2002) Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol 20:3992–3998PubMedCrossRefGoogle Scholar
  46. Jackson McCleary NA, Meyerhardt J, Green E et al (2009) Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: findings from the ACCENT Database. J Clin Oncol 27(15s): abstract 4010Google Scholar
  47. Jessup JM, Stewart A, Greene FL et al (2005) Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 294:2703–2711PubMedCrossRefGoogle Scholar
  48. Kahn KL, Adams JL, Weeks JC et al (2010) Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA 303:1037–1045PubMedCrossRefGoogle Scholar
  49. Kanesvaran R, Li H, Koo KN et al (2011) Analysis of prognostic factors of comprehensive geriatric assessment and development of a clinical scoring system in elderly Asian patients with cancer. J Clin Oncol 29:3620–3627PubMedCrossRefGoogle Scholar
  50. Keating NL, Landrum MB, Klabunde CN et al (2008) Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity? J Clin Oncol 26:2532–2537PubMedCrossRefGoogle Scholar
  51. Koh PK, Seow-Choen F (2006) Multicentre prospective randomized trials are not always relevant to surgeons. ANZ J Surg 76:286–287PubMedCrossRefGoogle Scholar
  52. Kuebler JP, Wieand HS, O’Connell MJ et al (2007) Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25:2198–2204PubMedCrossRefGoogle Scholar
  53. Lembersky BC, Wieand HS, Petrelli NJ et al (2006) Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 24:2059–2064PubMedCrossRefGoogle Scholar
  54. Lichtman SM (2003) Guidelines for the treatment of elderly cancer patients. Cancer Control 10:445–453PubMedGoogle Scholar
  55. Lyman GH (1998) Cancer care in the elderly. Cancer Control 5:347–354PubMedGoogle Scholar
  56. Mamounas E, Wieand S, Wolmark N et al (1999) Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17:1349–1355PubMedGoogle Scholar
  57. Meropol NJ, Egleston BL, Buzaglo JS et al (2008) Cancer patient preferences for quality and length of life. Cancer 113:3459–3466PubMedCrossRefGoogle Scholar
  58. Moertel CG, Fleming TR, Macdonald JS et al (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352–358PubMedCrossRefGoogle Scholar
  59. Moertel CG, Fleming TR, Macdonald JS et al (1995) Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’ B2 colon cancer. J Clin Oncol 13:2936–2943PubMedGoogle Scholar
  60. Muss HB, Biganzoli L, Sargent DJ, Aapro M (2007) Adjuvant therapy in the elderly: making the right decision. J Clin Oncol 25(14):1870–1875PubMedCrossRefGoogle Scholar
  61. Neugut AI, Matasar M, Wang X et al (2006) Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol 24:2368–2375PubMedCrossRefGoogle Scholar
  62. Newcomb PA, Carbone PP (1993) Cancer treatment and age: patient perspectives. J Natl Cancer Inst 85:1580–1584PubMedCrossRefGoogle Scholar
  63. NIH Consensus Conference (1990) Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444–1450CrossRefGoogle Scholar
  64. O’Connor ES, Greenblatt DY, LoConte NK et al (2011) Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 29:3381–3388PubMedCrossRefGoogle Scholar
  65. Poole C, Gardiner J, Twelves C et al (2002) Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol 49:225–234PubMedCrossRefGoogle Scholar
  66. Popescu RA, Norman A, Ross PJ et al (1999) Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 17:2412–2418PubMedGoogle Scholar
  67. Pubmed online search for publications whose title or abstract text contain the terms “elderly cancer patients” [Internet] (2011) [Updated 2011 Dec 5; cited 2011 Dec 5]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/
  68. Quipourt V, Jooste V, Cottet V et al (2011) Comorbidities alone do not explain the undertreatment of colorectal cancer in older adults: a French population-based study. J Am Geriatr Soc 59:694–698PubMedCrossRefGoogle Scholar
  69. Rosati G, Cordio S, Tucci A et al (2005) Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients. Oncology 69:122–129PubMedCrossRefGoogle Scholar
  70. Saltz LB, Niedzwiecki D, Hollis D et al (2007) Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 25:3456–3461PubMedCrossRefGoogle Scholar
  71. Sargent DJ, Goldberg RM, Jacobson SD et al (2001) A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345:1091–1097PubMedCrossRefGoogle Scholar
  72. Sargent DJ, Wieand HS, Haller DG et al (2005) Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23:8664–8670PubMedCrossRefGoogle Scholar
  73. Sargent DJ, Yothers GA, Green E et al (2010) Benefits and adverse events (AEs) in younger (Y) (age <50) versus older patients (pts) receiving adjuvant chemotherapy (AT) for colon cancer (CC): findings from the 33,574 pt ACCENT dataset. J Clin Olcol 28(15s): abstract 3523Google Scholar
  74. Scheithauer W, McKendrick J, Begbie S et al (2003) Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 14:1735–1743PubMedCrossRefGoogle Scholar
  75. Schmoll HJ, Cartwright T, Tabernero J et al (2007) Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 25:102–109PubMedCrossRefGoogle Scholar
  76. Schrag D, Cramer LD, Bach PB et al (2001) Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 93:850–857PubMedCrossRefGoogle Scholar
  77. Schrag D, Rifas-Shiman S, Saltz L et al (2002) Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 20:3999–4005PubMedCrossRefGoogle Scholar
  78. Schuller J, Cassidy J, Dumont E et al (2000) Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45:291–297PubMedCrossRefGoogle Scholar
  79. Seow A, Koh WP, Chia KS et al (2004) Trends in cancer incidence in Singapore 1968–2002. Singapore Cancer Registry Report no. 6Google Scholar
  80. Seymour MT, Thompson LC, Wasan HS et al (2011) Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet 377:1749–1759PubMedCrossRefGoogle Scholar
  81. Singapore Cancer Registry (2005–2009) Interim Annual Registry Report 2005–2009. National Registry of Diseases OfficeGoogle Scholar
  82. Singapore Department of Statistics (2011) Population trends. ISSN 1793 2424Google Scholar
  83. Stein BN, Petrelli NJ, Douglass HO et al (1995) Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 75:11–17PubMedCrossRefGoogle Scholar
  84. Sundararajan V, Mitra N, Jacobson JS et al (2002) Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 136:349–357PubMedGoogle Scholar
  85. Tabah-Fisch I, Maindrault-Goebel F, Benavides M et al (2002) Oxaliplatin/5 FU/LV is feasible, safe and active in elderly colorectal cancer (CRC) patients. Proc Am Soc Clin Olcol 21: abstract 556Google Scholar
  86. Tan KY, Konishi F, Suzuki K (2010) The evidence for adjuvant treatment of elderly patients (age  ≥  70) with stage III colon cancer is inconclusive. Surg Today 40:2–3Google Scholar
  87. Tournigand C, Andre T, Bachet J et al (2010) FOLFOX4 as adjuvant therapy in elderly patients (pts) with colon cancer (CC): subgroup analysis of the MOSAIC trial. J Clin Oncol 2(15s): abstract 3522Google Scholar
  88. Tsalic M, Bar-Sela G, Beny A et al (2003) Severe toxicity related to the 5-fluorouracil/leucovorin combination (the Mayo Clinic regimen): a prospective study in colorectal cancer patients. Am J Clin Oncol 26:103–106PubMedGoogle Scholar
  89. Twelves C, Wong A, Nowacki MP et al (2005a) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352:2696–2704PubMedCrossRefGoogle Scholar
  90. Twelves CJ, Butts CA, Cassidy J et al (2005b) Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study. Clin Colorectal Cancer 5:101–107PubMedCrossRefGoogle Scholar
  91. Twelves C, Scheithauer W, McKendrick J et al (2011) Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol. doi: 10.1093/annonc/mdr366
  92. Van Cutsem E, Hoff PM, Harper P et al (2004) Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 90:1190–1197PubMedCrossRefGoogle Scholar
  93. Van Cutsem E, Labianca R, Bodoky G et al (2009) Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 27:3117–3125PubMedCrossRefGoogle Scholar
  94. Wieland D, Hirth V (2003) Comprehensive geriatric assessment. Cancer Control 10:454–462PubMedGoogle Scholar
  95. Yancik R (2005) Population aging and cancer: a cross-national concern. Cancer J 11:437–441PubMedCrossRefGoogle Scholar
  96. Yancik R, Ries LA (2004) Cancer in older persons: an international issue in an aging world. Semin Oncol 31:128–136PubMedCrossRefGoogle Scholar
  97. Ychou M, Raoul JL, Douillard JY et al (2009) A phase III randomised trial of LV5FU2  +  irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol 20:674–680PubMedCrossRefGoogle Scholar
  98. Yellen SB, Cella DF, Leslie WT (1994) Age and clinical decision making in oncology patients. J Natl Cancer Inst 86:1766–1770PubMedCrossRefGoogle Scholar
  99. Zalcberg J, Kerr D, Seymour L et al (1998) Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group. Eur J Cancer 34:1871–1875PubMedCrossRefGoogle Scholar
  100. Zuckerman IH, Rapp T, Onukwugha E et al (2009) Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with stage III colon cancer. J Am Geriatr Soc 57:1403–1410PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Department of Medical OncologyNational Cancer CenterSingaporeSingapore

Personalised recommendations